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Summary We studied the effects of ICRF-154 in combination with 11 anticancer agents on four human
leukaemia cell lines. Cells were incubated for 3 days in the presence of two drugs (ICRF-154 and one other),
and cell growth inhibition was determined by MTT assay. Effects of drug combinations at the ID50 level were
analysed using the isobologram method (Steel). In the lymphoblastic leukaemia cell lines, MOLT-3, HSB, and
B-ALL, supra-additive effects were observed for ICRF-154 in combination with amsacrine, bleomycin,
doxorubicin, and etoposide. Additive effects were observed for its combinations with cisplatin, CPT-I1,
cytosine arabinoside, 5-fluorouracil, mitomycin C, and vincristine. Sub-additive to protective effects were
observed in combination with methotrexate. In an erythroleukaemia cell line, K-562, no drug showed
supra-additive effects with ICRF-154, while sub-additive to protective effects were observed for ICRF-154 in
combination with cisplatin and methotrexate. The other drugs showed additive effects with ICRF-154. These
results indicate that the combined effects of ICRF-154 with other agents vary, depending on the cell line.
Against lymphoid malignancies, ICRF-154 would be advantageous when administered simultaneously with
many anticancer agents. Of such agents, amsacrine, bleomycin, doxorubicin, and etoposide are the most
suitable, while methotrexate is least suitable for such combined treatment.
Bis(2,6-dioxopiperazine) derivatives, such as ICRF-159 and
ICRF-154, have been shown to have significant antitumour
activity against a variety of murine tumour cells (Creighton
et al., 1969; Herman et al., 1982), but their clinical applica-
tion in the 1970s was hampered by limited effectiveness
(Hellman et al., 1969; Creaven et al., 1975). The major
reason for this ineffectiveness was their inadequate
bioavailability, presumably due to poor solubility in both
water and organic solvents. Much effort has therefore been
directed toward finding more soluble and more active bis(2,6-
dioxopiperazine) analogues, in the hope that these would
demonstrate greater clinical efficacy. The search for new
synthetic derivatives has led to the development of a novel
analogue, known as MST-16 or 4,4-(1,2-ethanediyl)bis(l-
isobutoxycarbonyloxy-methyl-2,6-piperazinedione) (Figure 1)
(Narita et al., 1990). Its intestinal absorption rate was about
50%, and it was immediately metabolised to its parent com-
pound, ICRF-154 (Narita et al., 1991). Oral administration
of MST-16 is now under phase II study in Japan, and
preliminary results have shown that this agent is especially
active against leukaemia and lymphoma (Ichihashi et al.,
1990; Tominaga et al., 1990; Ohno et al., 1992). Clinical
combination therapy trials will start in the near future. To
date, however, few experimental data have been available on
the effects of drug combinations of bis(2,6-dioxopiperazine)
derivatives, e.g., ICRF-159 {(+)-1,2-bis(3,5-dioxopiperazinyl-
1-yl)propane) and ICRF-187 {(+)-1,2-bis(3,5-dioxopiper-
azinyl-1-yl) pro- pane) with other anticancer agents (Kline,
1974; Woodman, 1974; Woodman, 1975; Wadler et al., 1986)
and no data are available on ICRF-154 in combination with
other agents.
In the present study, we investigated the in vitro effects of
ICRF-154 in combination with commonly used anticancer
agents on four human leukaemia cell lines. The dose-response
curves for the combinations were obtained from a MTT
{3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazonium bromide)
assay (Mosmann, 1983), and the data were analysed with an
isobologram (Steel et al., 1979) that has been devleoped for
the evaluation of drug combinations (Kano et al., 1988).
Materials and methods
Cell line
Four human leukaemia cell lines were used for this study:
Two T-cell acute lymphoblastic leukaemia cell lines, MOLT-
3 (Minowada et al., 1972), and HSB-2 (Adams et al., 1968),
one B-cell acute lymphoblastic leukaemia cell line, BALL-2
(Kubonishi et al., 1991), and one erythroleukaemia cell line,
K-562 (Lozzio et al., 1975). All cell lines were maintained as
suspension cultures in culture flasks containing RPMI 1640
medium (Nissui Seiyaku Co. Ltd., Tokyo, Japan) supple-
mented with 10% heat-activated foetal calf serum (Flow Lab,
Rockville, MD).
Drugs
ICRF-154 was obtained from Zenyaku Kogyo Co. Ltd.,
Tokyo. Amsacrine was kindly provided by Dr Makoto
Ogawa (Cancer Chemotherapy Center, Tokyo). The other
agents used and their sources were: bleomycin, cisplatin, and
etoposide (Nihon Kayaku Co. Ltd., Tokyo), CPT-11 [7-
ethyl-10-{4-(1-piperidino)-l-piperidino)carbonyloxy campto-
thecin] (Yakult Co. Ltd., Tokyo), doxorubicin (Meiji Co.
Ltd., Tokyo), cytosine arabinoside (Nihon Shinyaku Co.
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Figure 1 Structures of MST-16 and ICRF-154.
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Ltd., Tokyo), 5-fluorouracil and mitomycin C (Kyowa
Hakko Co. Ltd., Tokyo), methotrexate (Lederle Japan Ltd.,
Tokyo), and vincristine (Shionogi Co. Ltd., Tokyo).
Cellgrowth inhibition by combined anticancer agents
On day 0, logarithmically growing cells were harvested from
the flasks and resuspended to a final concentration of either
1.5 x I0'cellsml-' (MOLT-3, HSB-2, and BALL-2), or
7.5 x i04cells ml' (K-562) in fresh medium containing 10%
FCS. Cell suspensions (100 tLI) were dispensed with a multi-
channel pipet into individual wells of a 96-well lidded tissue
culture plate (Falcon, Oxnard, CA). Each plate had one
8-well control column that contained medium alone and one
8-well control column that contained cells but no drugs. Four
plates were prepared for one drug-ICRF-154 combination.
Cells were incubated in a humidified atmosphere of 95%
air/5% CO2 at 37°C for 3 h. ICRF-154 was dissolved in
dimethyl sulfoxide and amsacrine was dissolved in distilled
water. All other drugs were dissolved in RPMI 1640 and
diluted in RPMI 1640 plus 10% FCS. Solutions of ICRF-154
and the second drug at different concentrations were then
added (50 l) to quadruplicate wells containing cell suspen-
sions, and the plates were subsequently incubated under iden-
tical conditions for 3 days.
MTT assay
On day 3, viable cell number was determined by a slightly
modified MTT assay (Kano et al., 1991). MTT solution was
prepared at 5 mg ml-' in PBS. The solution was diluted 1 to
5 in prewarmed medium, and 50jil was added to each culture
well. After 4 h incubation at 37°C with 5% C02, the plates
were emptied, and 150;l of dimethyl sulfoxide was added to
each well. After the plates were vigorously mixed to
solubilize the MTT-formazan product, absorbance at 570 nm
was measured with a Titertek multiscan plate reader. The
dose-response curves were plotted ona semilog scale as a
percentage of the control cell number, which was obtained
from samples with no drug exposure that were processed
simultaneously.
Isobologram analysis
The effects of ICRF-154 in combination with other agents at
the ID50 point were analysed by an isobologram method
(Steel). The theoretical basis of this method has been de-
scribed previously (Steel et al., 1979; Kano et al., 1988; Kano
et al., 1992). Based upon the dose-response curves of ICRF-
154 other drug combinations, three isoeffect lines, mode I
and mode II, were drawn (Figure 2). When the data points of
the drug combination fall within the area surrounded by the
three lines (envelope of additivity) (Pb), this combination is
regarded as additive. When the data points fall to the left of
the envelope, the two drugs have supra-additive interaction
(synergism). When the data points fall to the right of the
envelope (Pa), but within or the square dot line (Pc), the two
drugs have sub-additive interaction. When the points are
outside the square (Pd), this combination is regarded as
protective interaction. Both sub-additive and protective
interactions are considered to be antagonism. We repeated
each experiment at least three times. In each experiment, the
dose-response curves of ICRF-154 and the combined drugs
were slightly different, but a similar tendency was observed.
Representative dose-response curves and isobolograms are
shown.
Results
Combined effects ofICRF-154 with other agents in MOLT-3
Figure 3a-d shows the typical dose-response curves of com-
binations of ICRF-154 with cisplatin (CDDP), doxorubicin
(DOX), etoposide (VP-16), and methotrexate (MTX), respec-
tively, in MOLT-3 cells. Based upon these dose-response
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Figure 2 An envelope of additivity constructed from the dose-
response curves of two drugs (ICRF-154 and a combined drug).
Data points Pa, Pb, Pc, and Pd show supra-additive, additive,
sub-additive, and protection, respectively (see text).
curves, isobolograms were made (Figures 4 and 5). In
MOLT-3 cells, the combined data points for simultaneous
and continuous exposure to ICRF-154 and amsacrine (AMSA)
fell on the left side of the envelope (Figure 4a). This observa-
tion was interpreted to show that simultaneous exposure to
ICRF-154 and amsacrine produced supra-additive effects.
Similar tendencies were observed for ICRF-154 in combina-
tion with bleomycin (BLM), doxorubicin, and etoposide
(Figure 4b, f, g). For ICRF-154 combined with cisplatin
(Figure 4c), the data points fell within the envelope of
additivity. Similar interaction was observed for ICRF-154 in
combination with, CPT-11, cytosine arabinoside (ara-C) 5-
fluorouracil (5-FU), mitomycin C (MMC), and vincristine
(VCR) (Figure 4d, e, h, j, k). For the simultaneous and
continuous exposure of these cells to ICRF-154 and metho-
trexate, all the data points fell within the areas of sub-
additivity and protection (Figure 4i).
Combinedeffects ofICRF-154 with other agents in HSB-2,
B-ALL-2, and K-562 cells
In HSB-2 and B-ALL-2 cells, the combined effects of ICRF-
154 with other agents were quite similar to those shown in
MOLT-3 cells. The isobolograms of ICRF-154 in combina-
tion with amsacrine, bleomycin, doxorubicin, etoposide, and
methotrexate, which showed supra-additive or sub-additive
to protective effects with ICRF-154 against MOLT-3 cells,
are shown in Figure Sa-j. For the combinations of ICRF-
154 with amsacrine, bleomycin, doxorubicin, and etoposide,
the combined data points mainly fell on the left side of the
envelope in HSB-2 and B-ALL-2, except for those for ICRF-
154 with bleomycin in B-ALL-2, which fell in the envelope of
additivity (Figure Sa-d, Sf-i). For ICRF-154 with cisplatin,
CPT-11, cytosine arabinoside, 5-fluorouracil, mitomycin C,
and vincristine, the data points mainly fell in the envelope of
additivity (data not shown). For ICRF-154 with methotrex-
ate, the data points fell within the areas of sub-additivity and
protection (Figure Se, j).
The combined effects of ICRF-154 with amsacrine, bleo-
mycin, cisplatin, doxorubicin, and etoposide in K-562 cells
differed from those in MOLT-3. The isobolograms of ICRF-
154 in combination with amsacrine, bleomycin, cisplatin,
doxorubicin, etoposide, and methotrexate against K-562 cells
are shown in Figure 5k-p. For ICRF-154 with amsacrine,
bleomycin, doxorubicin, and etoposide, the data points fell
within the envelope of additivity, while for ICRF-154 with
cisplatin and methotrexate, the data points fell within the
areas of sub-additivity and protection.
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Figure 3 Dose-response curves of ICRF-154 in combination with a, cisplatin (CDDP); b, doxorubicin (DOX); c, etoposide
(VP-16); and d, methotrexate (MTX) in MOLT-3. Each assay was run in quadruplicate, and cell growth number was plotted as a
percentage of control (cells not exposed to drugs). The concentrations of CDDP, DOX, VP-16, and MTX for each symbol are
shown in the upper right of a, b, d, and d, respectively. ICRF-154 concentrations are shown on the abscissa.
Discussion
Analysis of the effects of drug-drug interaction was carried
out by an improved isobologram method for the evaluation
of the effects of radiation-drug interaction (Steel et al., 1979).
Using this method, we have demonstrated supra-additive
(synergistic) cytotoxic effects of combinations of ICRF-154
with amsacrine, bleomycin, doxorubicin, and etoposide on
three human lymphoblastic leukaemia cell lines in vitro.
Since, in general, the improved isobologram method defines
supra-additive effects (synergy) more strictly than other
methods such as the isobologram (Loewe, 1953), the frac-
tional product concept (Valeriotte et al., 1975), and the
median effect plot principle (Chou et al., 1985), these com-
binations would be also synergistic when evaluated by these
other methods.
There have been no experimental data reported for ICRF-
154 or MST-16 in combination with anticancer agents, but
several studies have been done on other bis(2,6-dioxo-
piperazine) derivatives (Kline, 1974; Woodman, 1974; Wood-
man et al., 1975; Wadler et al., 1986). Woodman et al. and
Kline et al. showed positive interaction between anthracy-
clines and ICRF-159 in L-1210 bearing mice (Kline, 1974;
Woodman et al., 1975). Wadler et al. and Monti et al.,
demonstrated synergistic interaction between ICRF-187 and
doxorubicin against the murine sarcoma S180 cell line and
the human promyelocytic leukaemia HL-60 cell line, respec-
tively, in vitro (Wadler et al., 1986; Monti et al., 1990). Our
data with three lymphoblastic cell lines are in agreement with
these previous findings. In addition to this favourable inter-
action, bis(2,6-dioxopiperazine) derivatives have protective
effects against anthracycline cardiotoxicity (Herman et al.,
1981; Fisher et al., 1986). Since the dose-limiting factor of
anthracyclines is their cardiotoxicity, the protection afforded
against cardiotoxicity by bis(2,6-dioxopiperazine) derivatives
may allow an increase in total anthracycline dose with a
consequent increase in antitumour activity. MST-16 has a
similar protective effect on doxorubicin-treated animals
(Yoshida et al., 1991). Both synergism and the alleviation of
cardiotoxicity indicate the usefulness of the simultaneous
administration of MST-16 with doxorubicin.
To our knowledge, there have been no experimental data
on combinations of bis(2,6-dioxopiperazine) derivatives with
amsacrine, bleomycin, or etoposide. In the present study,
ICRF-154 showed supra-additive effects with amsacrine,
bleomycin, and etoposide, as well as with doxorubicin,
against lymphoblastic cell lines. Supra-additive effects were
not seen with combinations of bleomycin, doxorubicin, or
etoposide and other anticancer agents which we also used in
this study (Kano et al., unpublished data) and only cytosine
arabinoside showed a supra-additive effect with amsacrine
when subjected to the same assay as that used in this study
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Figure 4 Isobolograms of ICRF-154 in combination with a, amsacrine (AMSA); b, bleomycin (BLM); c, cisplatin (CDDP); d,
CPT-11; E, cytosine arabinoside (ara-C); f, doxorubicin (DOX); g, etoposide (VP-16); h, 5-fluorouracil (5-FU); i, methotrexate
(MTX); j, mitomycin C (MMC); and k, vincristine (VCR) in MOLT-3.
(Kano et al., 1991). Thus, MST-16 (ICRF-154) would appear
to be one of the most favourable agents for combination
with amsacrine, bleomycin, doxorubicin, and etoposide.
MST-16 in combination with these agents would produce
significant clinical response against lymphoid malignancies.
In recent years, prolonged oral etoposide therapy has had
high response rates for malignant lymphoma, leukaemia,
lung cancer, and germ cell tumours (Greco et al., 1990). As
MST-16 is also administered orally for a few days to a few
weeks (Tominaga et al., 1990; Ohno et al., 1992), the simul-
taneous administration of oral etoposide and MST-16 is to
be recommended. Complete remission has been observed in
some cases of adult T-cell leukaemia, which is refractory to
intensive chemotherapy, when oral etoposide (Sampi et al.,
1985) or MST-16 (Ichihashi et al., 1990) was used. The
combination of oral etoposide and MST-16 would be more
effective against adult T-cell leukaemia than either agent used
singly and is worthy of clinical trial in this case also.
The mechanisms underlying the synergistic interaction
between ICRF-154 and these agents are obscure. ICRF-187
has been reported to enhance free radical formation from
doxorubicin without affecting doxorubicin uptake in HL-60
cells (Monti et al., 1990). This may be one of the mechanisms
underlying the synergistic interaction of bis(2,6-dioxo-
piperazine) derivatives and doxorubicin. Although there is
still considerable controversy over the mechanism of action
of bis(2,6-dioxopiperazine) derivatives (Herman et al., 1982;
Sharpe et al., 1970), recent data suggest that topoisomerase-
II is involved in their action (Ishida et al., 1991). Amsacrine,
doxorubicin, and etoposide, which show supra-additive
effects with ICRF-154, are also topoisomerase-IT reactive
agents (Tewey et al., 1984; Ross et al., 1985). However,
bis(2,6-dioxopiperazine) derivatives do not cause formation
of a cleavable complex as do the anticancer agents, amsa-
crine, anthracyclines, and etoposide (Tanabe et al., 1991). We
were unable to find any supra-additive effects among amsa-
crine, doxorubicin, and etoposide (Kano et al., unpublished
data), or between ICRF-154 and the topoisomerase-I
inhibitor, CPT-1 1 (Hsiang et al., 1985) against MOLT-3 cells.
Whether amsacrine, doxorubicin, and etoposide enhance
ICRF-154 cytotoxicity or vice versa is obscure. However,
only additive effects were observed between ICRF-154 and
doxorubicin in K-562 cells and a human colon carcinoma cell
line WiDr (data not shown). The mechanisms underlying
these differing interactions in lymphoblastic and other cell
lines are not known. Cells of lymphoblastic and myelogenous
lines respond to topoisomerases I and II in a very different
fashion (Del Bino et al., 1991). The use of available tech-
niques to study DNA topoisomerases may enable the eluci-
dation of the differing cytotoxic mechanisms of topoisomerase
inhibitors in combinations against malignant cells of different
histological origin.
Our data show that cisplatin had additive effects with
ICRF-154 against three lymphoblastic leukaemia cell lines,
while it had sub-additive to protective effects against K-562
cells and WiDr (data not shown). Cytosine arabinoside had
additive effects with ICRF-154 against all cell lines studied.
With respect to the survival of leukaemic mice, the effect of
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Figure 5 Isobolograms of ICRF-154 in combination with other agents in HSB (a-e), B-ALL (f-j), and K-562. (k-p). The agents
combined with ICRF-154 are; a, f, k, amsacrine (AMSA); b, g, 1, bleomycin (BLM); m, cisplatin (CDDP); c, h, n, doxorubicin
(DOX), d, i, o, etoposide (VP-16); and e, j, p, methotrexate (MTX).
cisplatin or cytosine arabinoside in combination with ICRF-
159 on survival has been reported to be significantly superior
to that of either single agent (Kline, 1974).
However, the enhanced activity of a drug combination,
whether in animal experiments or in clinical studies, does not
require a supra-additive (synergistic) effect. By improved
isobologram analysis, additive and even sub-additive effects
can show the superiority of drug combinations. Therefore,
CPT-l 1, 5-fluorouracil, mitomycin C, and vincristine, which
also showed additive effects with ICRF-154 in our experi-
ment, would be expected to have a stronger cytotoxic effect
in combination with ICRF-154 (MST-16) than the single
agents in both animal and clinical studies.
Our data show that methotrexate had sub-additive and
protective effects with ICRF-154 against all leukaemic cell
lines studied. Protection means superiority of the single
agents to the combination in terms of effectiveness. In
leukaemic mice, the combination of ICRF-159 with metho-
trexate has been reported to produce an increase in life span
only slightly greater than that found when either drug was
used separately (Kline, 1974). These findings suggest that the
simultaneous administrations of ICRF-154 (MST-16) with
methotrexate is unlikely to be advantageous, even though the
two drugs have no cross resistance. The mechanisms underly-
ing the antagonistic effects of these combinations are unclear.
If ICRF-154 (MST-16) is combined with methotrexate, other
suitable schedules should be explored, since the administra-
tion schedule (exposure) of drugs may have great influence
on the effects of drug combinations (Kano et al., 1988).
In conclusion, we have shown that the effects of ICRF-154
in combination with other anticancer agents are variable. Of
the anticancer agents we studied, amsacrine, bleomycin,
doxorubicin, and etoposide showed supra-additive effects
with ICRF-154 against lymphoblastic leukaemia cell lines.
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Combinations of ICRF-154 (MST-16) with these agents
should produce a significant clinical response. However, more
investigations are necessary to study the effects of ICRF-154
(MST-16) in combination in various cell lines, to ascertain
the exact mechanism of this synergism with other agents in
lymphoblastic leukaemia cell lines, and to evaluate the toxi-
city of these combinations. In contrast, methotrexate had an
antagonsitic effect with ICRF-154 in all cell lines studied,
suggesting that simultaneous administration of these two
agents would provide little benefit in the treatment of cancer.
Although there are gaps between in vitro studies and
clinical trials, these data should provide useful information
for the establishment of clinical protocols involving MST-16
ICRF-154 (MST-16).
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